Baxter International Inc. (BAX) FCF Payout Ratio: 14.37%
Is Baxter International Inc.’s FCF payout ratio high or low?
Baxter International Inc.'s FCF payout ratio of 14.37% is 80% below its 5-year average of 72.27%, near the low end of its 5-year range (14.37%–107.74%).
86.53% below its 12-month average of 106.64%.
BAX FCF Payout Ratio Chart
BAX Average FCF Payout Ratio Chart
BAX Current vs Average FCF Payout Ratio Chart
BAX FCF Payout Ratio Metrics
FCF PAYOUT RATIO
14.37%
FCF PAYOUT RATIO AVG TTM
106.64%
FCF PAYOUT RATIO AVG 3Y
89.55%
FCF PAYOUT RATIO AVG 5Y
72.27%
FCF PAYOUT RATIO AVG 10Y
59.50%
FCF PAYOUT RATIO AVG 15Y
53.54%
FCF PAYOUT RATIO AVG 20Y
48.72%
CURRENT VS TTM AVG
-86.53%
CURRENT VS 3Y AVG
-83.95%
CURRENT VS 5Y AVG
-80.12%
CURRENT VS 10Y AVG
-75.85%
CURRENT VS 15Y AVG
-73.16%
CURRENT VS 20Y AVG
-70.50%
Payout Ratio Comparison
FCF Payout Ratio
14.4%
Earnings Payout Ratio
N/A
Dividend Yield
0.98%
FCF Yield
6.77%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $323.00M | $348.00M | 107.7% |
| 2024 | $559.00M | $590.00M | 105.5% |
| 2023 | $1.29B | $586.00M | 45.4% |
| 2022 | $576.00M | $573.00M | 99.5% |
| 2021 | $1.53B | $530.00M | 34.6% |
| 2020 | $1.16B | $473.00M | 40.8% |
| 2019 | $1.41B | $423.00M | 30.0% |
| 2018 | $1.36B | $376.00M | 27.7% |
| 2017 | $1.10B | $315.00M | 28.7% |
| 2016 | $935.00M | $268.00M | 28.7% |
| 2015 | $860.00M | $910.00M | 105.8% |
| 2014 | $2.29B | $1.09B | 47.8% |
| 2013 | $2.49B | $1.02B | 41.1% |
| 2012 | $1.95B | $804.00M | 41.3% |
| 2011 | $1.86B | $709.00M | 38.2% |
| 2010 | $2.04B | $688.00M | 33.7% |
| 2009 | $1.90B | $632.00M | 33.4% |
| 2008 | $1.56B | $546.00M | 35.0% |
| 2007 | $1.61B | $704.00M | 43.6% |
| 2006 | $1.66B | $364.00M | 22.0% |
| 2005 | $1.11B | $359.00M | 32.5% |
| 2004 | $822.00M | $361.00M | 43.9% |
| 2003 | $636.00M | $346.00M | 54.4% |
| 2002 | $345.00M | $349.00M | 101.2% |
| 2001 | $327.00M | $341.00M | 104.3% |
| 2000 | $491.00M | $84.00M | 17.1% |
| 1999 | $452.00M | $338.00M | 74.8% |
| 1998 | $383.00M | $331.00M | 86.4% |
| 1997 | $104.00M | $316.00M | 303.8% |
| 1996 | $395.00M | $320.00M | 81.0% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Baxter International Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Baxter International Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Baxter International Inc. (BAX)?
- The FCF payout ratio for BAX stock is 14.37%.
- Is Baxter International Inc.'s FCF payout ratio high or low?
- Baxter International Inc.'s FCF payout ratio of 14.37% is 80% below its 5-year average of 72.27%, near the low end of its 5-year range (14.37%–107.74%).
- What is the TTM average FCF payout ratio for Baxter International Inc. (BAX)?
- The TTM average FCF payout ratio for BAX stock is 106.64%.
- What is the 3Y average FCF payout ratio for Baxter International Inc. (BAX)?
- The 3Y average FCF payout ratio for BAX stock is 89.55%.
- What is the 5Y average FCF payout ratio for Baxter International Inc. (BAX)?
- The 5Y average FCF payout ratio for BAX stock is 72.27%.
- What is the 10Y average FCF payout ratio for Baxter International Inc. (BAX)?
- The 10Y average FCF payout ratio for BAX stock is 59.50%.
- What is the 15Y average FCF payout ratio for Baxter International Inc. (BAX)?
- The 15Y average FCF payout ratio for BAX stock is 53.54%.
- What is the 20Y average FCF payout ratio for Baxter International Inc. (BAX)?
- The 20Y average FCF payout ratio for BAX stock is 48.72%.
Baxter International Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 107.74% |
| 2024-12-31 | 105.55% |
| 2023-12-31 | 45.43% |
| 2022-12-31 | 99.48% |
| 2021-12-31 | 34.62% |
| 2020-12-31 | 40.81% |
| 2019-12-31 | 30.04% |
| 2018-12-31 | 27.69% |
| 2017-12-31 | 28.69% |
| 2016-12-31 | 28.66% |
| 2015-12-31 | 105.81% |
| 2014-12-31 | 47.82% |
| 2013-12-31 | 41.05% |
| 2012-12-31 | 41.34% |
| 2011-12-31 | 38.18% |
| 2010-12-31 | 33.73% |
| 2009-12-31 | 33.35% |
| 2008-12-31 | 34.98% |
| 2007-12-31 | 43.65% |
| 2006-12-31 | 21.97% |
| 2005-12-31 | 32.46% |
| 2004-12-31 | 43.92% |
| 2003-12-31 | 54.40% |
| 2002-12-31 | 101.16% |
| 2001-12-31 | 104.28% |
| 2000-12-31 | 17.11% |
| 1999-12-31 | 74.78% |
| 1998-12-31 | 86.42% |
| 1997-12-31 | 303.85% |
| 1996-12-31 | 81.01% |
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider